# Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

> **NCT01275222** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 117 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** RAD001
- **DRUG:** Imatinib 600mg/day (Glevec is the brand name for imatinib)
- **DRUG:** Imatinib 800mg/day (Glevec is the brand name for imatinib)

## Key facts

- **NCT ID:** NCT01275222
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11-13
- **Primary completion:** 2008-09-03
- **Final completion:** 2008-09-03
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2021-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01275222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01275222, "Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01275222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*